Safety of switching between rituximab biosimilars in onco-hematology
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-85563-1
Abstract: Comparable clinical efficacy and safety of the reference rituximab (MABTHERA) and its biosimilars has been established in randomized trials. However, safety concerns are often raised when switching from reference to biosimilar products and between different… read more here.
Keywords: hematology; safety; safety switching; rituximab biosimilars ... See more keywords